102 related articles for article (PubMed ID: 21420574)
1. [Liver toxicity of micafungin. Is this drug safe?].
Valerio M; Muñoz P; Bouza E
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():29-32. PubMed ID: 21420574
[TBL] [Abstract][Full Text] [Related]
2. [Why might micafungin be the drug of choice in pediatric patients?].
Ramos Amador JT; Prieto Tato L; Guillén Martín S
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():23-8. PubMed ID: 21420573
[TBL] [Abstract][Full Text] [Related]
3. Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases.
Cornely OA; Pappas PG; Young JA; Maddison P; Ullmann AJ
Expert Opin Drug Saf; 2011 Mar; 10(2):171-83. PubMed ID: 21306282
[TBL] [Abstract][Full Text] [Related]
4. [Is micafungin useful in the prophylaxis of invasive fungal disease in hematological patients?].
Salavert M; Jarque I
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():43-9. PubMed ID: 21420577
[TBL] [Abstract][Full Text] [Related]
5. Micafungin: new drug. Severe candidiasis: a third echinocandin, with life-threatening hepatotoxicity.
Prescrire Int; 2009 Aug; 18(102):154. PubMed ID: 19743568
[No Abstract] [Full Text] [Related]
6. Safety of high-dose micafungin for patients with hematological diseases.
Yamazaki S; Nakamura F; Yoshimi A; Ichikawa M; Nannya Y; Kurokawa M
Leuk Lymphoma; 2014 Nov; 55(11):2572-6. PubMed ID: 24460099
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis associated with micafungin use in a preterm infant.
King KY; Edwards MS; Word BM
J Perinatol; 2009 Apr; 29(4):320-2. PubMed ID: 19325554
[TBL] [Abstract][Full Text] [Related]
8. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
Mehta PA; Vinks AA; Filipovich A; Bleesing J; Jodele S; Jordan MB; Marsh R; Tarin R; Edwards S; Fearing D; Lawrence J; Davies SM
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1458-62. PubMed ID: 20546908
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study.
Yamaguchi M; Kurokawa T; Ishiyama K; Aoki G; Ueda M; Matano S; Takami A; Yamazaki H; Sawazaki A; Yamauchi H; Yoshida T; Nakao S
Ann Hematol; 2011 Oct; 90(10):1209-17. PubMed ID: 21695388
[TBL] [Abstract][Full Text] [Related]
10. Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials.
Manzoni P; Wu C; Tweddle L; Roilides E
Pediatr Infect Dis J; 2014 Nov; 33(11):e291-8. PubMed ID: 24892849
[TBL] [Abstract][Full Text] [Related]
11. [Micafungin: new challenges, new possibilities in the treatment of invasive fungal infection].
Pemán J; Torre-Cisneros J
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():1-2. PubMed ID: 21420569
[No Abstract] [Full Text] [Related]
12. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
[TBL] [Abstract][Full Text] [Related]
13. Safety of micafungin in pediatric clinical trials.
Arrieta AC; Maddison P; Groll AH
Pediatr Infect Dis J; 2011 Jun; 30(6):e97-e102. PubMed ID: 21378595
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders.
Tamura K; Urabe A; Yoshida M; Kanamaru A; Kodera Y; Okamoto S; Maesaki S; Masaoka T
Leuk Lymphoma; 2009 Jan; 50(1):92-100. PubMed ID: 19172498
[TBL] [Abstract][Full Text] [Related]
15. Caspofungin versus micafungin in the incidence of hepatotoxicity in patients with normal to moderate liver failure.
Shibata Y; Hagihara M; Kato H; Kawasumi N; Hirai J; Nishiyama N; Asai N; Koizumi Y; Yamagishi Y; Matsuura K; Mikamo H
J Infect Chemother; 2017 Jun; 23(6):349-353. PubMed ID: 28431933
[TBL] [Abstract][Full Text] [Related]
16. Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study.
Schneeweiss S; Carver PL; Datta K; Galar A; Johnson MD; Johnson MG; Marty FM; Nagel J; Najdzinowicz M; Saul M; Shoham S; Silveira FP; Varughese CA; Wilck M; Weatherby L; Auton T; Walker AM
J Antimicrob Chemother; 2016 Oct; 71(10):2938-44. PubMed ID: 27407049
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials.
Chen Q; Lin MH; Chen ML; Liu ZY; Chai D; Wang R
Chin Med J (Engl); 2012 Jan; 125(2):345-51. PubMed ID: 22340571
[TBL] [Abstract][Full Text] [Related]
18. [Micafungin, a new candin for the treatment of invasive mycoses].
Del Palacio A; Pontón J; Quindós G
Rev Iberoam Micol; 2009 Mar; 26(1):1. PubMed ID: 19463270
[No Abstract] [Full Text] [Related]
19. [Differential pharmacokinetic characteristics of micafungin. Experience in special populations].
Grau Cerrato S; Luque Pardos S; Ferrández Quirante O
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():10-4. PubMed ID: 21420571
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of micafungin for prophylaxis against invasive fungal infections in Japanese patients undergoing hematopoietic stem cell transplantation: Results of a post-marketing surveillance study.
Kobayashi C; Hanadate T; Niwa T; Hirano Y; Yoshiyasu T; So M; Matsui K
J Infect Chemother; 2015 Jun; 21(6):438-43. PubMed ID: 25749360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
